ArticleVeterinary world2025
Evaluation of serum alpha-1B glycoprotein and C-reactive protein levels as biomarkers of canine benign prostatic hyperplasia.
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Benign prostatic hyperplasia (BPH) is a prevalent disorder in aging male dogs, characterized by prostate enlargement secondary to hormonal dysregulation and chronic inflammation. Identifying non-invasive biomarkers is crucial for improving diagnosis and monitoring therapeutic interventions. This study aimed to evaluate serum alpha-1B glycoprotein (A1BG) and C-reactive protein (CRP) concentrations in dogs with BPH before and after castration, to assess their diagnostic and prognostic utility. Materials and Methods: A total of 20 male dogs were assigned to two groups: healthy controls (n = 10) and BPH-affected dogs (n = 10). Blood samples were collected from controls and the BPH group at diagnosis and 1 month post-castration. Serum A1BG and CRP concentrations were measured using enzyme-linked immunosorbent assay and fluorescence immunoassay, respectively. Prostatic volume (PV) was evaluated ultrasonographically. Results: Dogs with BPH demonstrated significantly lower serum A1BG concentrations before castration compared to healthy controls (p < 0.01) and post-castration (p < 0.01). Post-castration A1BG levels were comparable to controls, suggesting biochemical normalization. Serum CRP concentrations remained within the normal range (<30 mg/L) across all groups and showed no significant differences. A significant negative correlation was observed between age and A1BG concentration in the pre-castration BPH group (r = -0.74, p = 0.02). Castration resulted in a marked reduction in PV, consistent with therapeutic response. Conclusion: Serum A1BG demonstrated potential as a sensitive biomarker for the diagnosis and therapeutic monitoring of canine BPH, in contrast to CRP, which exhibited limited diagnostic value. Normalization of A1BG levels post-castration supports its role in reflecting disease resolution. Integrating A1BG assessment into veterinary diagnostic workflows could enhance early detection, monitoring, and management strategies for BPH, offering a non-invasive and clinically informative approach. Further longitudinal studies with larger cohorts are warranted to validate these findings and explore long-term biomarker dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.